Two different jobs in the hip joint

Most patients asking about ChondroFiller injection and PRP for the hip assume they are choosing between two versions of the same thing. They are not. These two treatments address fundamentally different problems in the hip joint, and in clinical practice they are rarely in direct competition — the type of cartilage damage, not personal preference, is what determines which is appropriate.

ChondroFiller injection is a structural treatment. A cell-free Type I collagen gel is placed into a discrete, focal cartilage defect under ultrasound guidance, where it sets in situ within minutes and forms a three-dimensional scaffold. The patient's own progenitor cells migrate into that matrix to begin tissue repair — a physical answer to a physical void.

PRP works entirely differently. A small blood draw is centrifuged to concentrate platelets, which — when injected into the hip joint — release growth factors that reduce inflammation and support the remaining cartilage. No scaffold is created; the aim is to modify the joint's biological environment.

Both are delivered by intra-articular injection under image guidance. Beyond that shared route, they do categorically different jobs.

Focal defect or diffuse wear: what the MRI shows

Hip MRI does more than confirm that cartilage is damaged — it reveals the pattern of that damage, and it is the pattern, not the pain score, that guides treatment selection.

A focal chondral defect is a discrete, contained area where cartilage has worn through completely (Grade III or IV on the ICRS scale), leaving a defined void in the joint surface with relatively intact surrounding cartilage. This is the territory where a ChondroFiller injection is clinically appropriate: the collagen scaffold needs healthy cartilage borders to anchor to and a structural void to fill.

Diffuse wear presents differently on MRI: cartilage thins across a broader zone rather than forming a single contained lesion. This pattern is characteristic of early-to-moderate hip osteoarthritis and is the environment where PRP tends to be most useful — modifying joint biology across a wide area rather than filling a specific gap.

Tönnis grading offers a practical guide to overall joint status. In published series, patients with Tönnis grade 2–3 osteoarthritis have fared poorly with scaffold-based cartilage repair; Tönnis ≤2 is generally needed for a ChondroFiller injection to be clinically appropriate. Tönnis grade is one factor within a broader assessment — not a blunt standalone cutoff.

Some patients present with a focal defect alongside low-grade diffuse changes. In those cases, both treatments may have a role at different stages: ChondroFiller addressing the structural void and PRP supporting the wider joint environment.

How ChondroFiller injection works in the hip

The product itself contains no cells — a distinction worth clarifying because patients often assume that a regenerative treatment must involve donor tissue or a harvest from their own body. ChondroFiller injection is acellular: a purified Type I collagen hydrogel manufactured without any living biological components. The repair biology comes entirely from the patient's own hip joint environment.

Delivered as an ultrasound-guided outpatient injection under local anaesthetic, the liquid collagen is placed directly into the focal defect in the hip joint. Within three to five minutes it polymerises in situ — transitioning from a liquid to a stable gel that sits within the void and conforms to its shape, forming a three-dimensional scaffold.

What follows is biology-led. The patient's own progenitor cells from the surrounding hip tissue begin migrating into the collagen matrix. Ex vivo work using human osteochondral tissue has confirmed that active cell recruitment starts within approximately two weeks of the scaffold making contact with joint tissue. Those cells populate the matrix and gradually deposit new cartilage-like material within it — a process described as matrix-induced chondrogenesis, where the scaffold's physical architecture guides the type and pattern of repair tissue that forms.

Tissue maturation is gradual: meaningful improvement in the hip typically continues across a 6–24 month window as those cells remodel and consolidate the matrix.

One technical factor is critical: accurate volume placement during the injection. Overfilling the defect can shift the repair tissue towards a fibrous composition rather than the denser, hyaline-like material that produces durable symptom relief.

How PRP works in the hip joint

Rather than introducing a foreign material into the joint, PRP works entirely through the patient's own biology. A small blood draw — typically 15–60 ml — is centrifuged to separate and concentrate the platelet-rich fraction, which is then injected into the hip joint under ultrasound or fluoroscopic guidance.

The active step happens after injection. Platelets in the hip joint environment become activated and release a cascade of growth factors from their alpha-granules: TGF-β, which drives collagen and extracellular matrix production; PDGF, which attracts reparative cells to the area; IGF-1, which promotes chondrocyte proliferation; and FGF and VEGF, which contribute to vascular support and tissue repair signalling. Liang et al. (2022), in a review cited more than 65 times, organise PRP's effects on articular cartilage into four domains: anti-inflammation, support for angiogenesis, cartilage protection, and direct cellular effects on chondrocytes.

None of this constitutes a structural repair. PRP does not fill a cartilage void, does not add physical material to the joint surface, and does not produce new, thick hyaline cartilage visible on MRI. That is not a shortcoming — it reflects what PRP is correctly used for. As a disease-modifier, it works on the biological environment of the hip joint: reducing the inflammatory signalling that accelerates cartilage breakdown, and creating conditions more favourable to the chondrocytes still present.

This makes PRP well matched to early-to-moderate hip osteoarthritis, where diffuse wear rather than a focal defect is the picture on MRI and where the aim is to slow progression and manage symptoms. Effects can last up to a year or more — typically longer than hyaluronic acid — making it a practical option for patients who are not yet candidates for a structural repair procedure, or who need joint support while weighing their next steps. The mechanistic evidence for these effects is robust; hip-specific randomised outcome data remain more limited than the equivalent knee literature, and individual responses vary depending on preparation method and joint status.

What the clinical evidence shows

The strongest hip-specific evidence for either treatment comes from a prospective cohort by Mazek et al. (JHPS 2021, PMC8460160), in which 26 adults with acetabular cartilage lesions larger than 2 cm² and concurrent femoroacetabular impingement underwent ChondroFiller gel placement during hip arthroscopy. At follow-up between three and five years, 17 of 21 evaluable patients — approximately 81% — achieved good or excellent results, with a mean Harris Hip Score gain of around 33 points. MRI confirmed statistically significant cartilage healing improvement versus pre-treatment status.

That result sits within a broader pattern: across multi-joint published cohorts, ChondroFiller achieves meaningful symptom relief — defined as measurable pain reduction and functional improvement — in 70–85% of treated patients.

Patient selection is the variable that most clearly separates outcomes within the cohort. Subjects with pre-existing Tönnis grade 2–3 osteoarthritis fared poorly. This extends the candidacy point made earlier: the scaffold mechanism depends on a joint environment capable of sustaining cell migration and tissue maturation over months. Where background degeneration is sufficiently advanced, the biological conditions needed to populate the collagen matrix may be compromised — which is why imaging assessment remains central even when the injectable route applies to a broader candidacy range than the arthroscopic surgical cohort.

On the PRP side, the mechanistic evidence — organised across four domains by Liang et al. (2022, 65+ citations) — is robust and well-cited. Hip-specific randomised outcome data are more limited than the equivalent knee literature, however, and individual responses vary with preparation method and joint status. PRP's biological role as a disease-modifier is clinically well supported; precise quantified hip-specific benefit continues to be investigated.

Critically, no randomised controlled trial directly comparing ChondroFiller injection with PRP in the hip joint has been identified in the published literature. That gap does not undermine either treatment — both address distinct clinical problems — but head-to-head outcome comparisons currently rest on mechanistic reasoning and cohort data rather than trial evidence.

Which patients suit which treatment and when both apply

For a focal, contained hip cartilage defect confirmed on MRI — full-thickness loss with substantially intact subchondral bone and no generalised osteoarthritis (Tönnis grade ≤2) — a ChondroFiller injection addresses the structural problem directly. The scaffold fills the defined void and recruits the patient's own cells to mature within it over subsequent months; this depends on a joint environment capable of sustaining that repair, which is why overall joint status continues to matter even through the injectable route.

PRP suits a different clinical picture: early-to-moderate diffuse hip cartilage degeneration, where MRI shows widespread thinning rather than a contained void. The aim is biological — reducing inflammatory signalling, slowing cartilage breakdown, and managing symptoms while monitoring progression. It is also appropriate for patients who are not yet at the threshold for a structural repair procedure and need joint support while weighing their next steps.

The two treatments are not alternatives for the same lesion. A focal defect needs structural restoration; diffuse wear needs biological support. Applying a collagen scaffold to a diffuse degenerative hip mismatches the tool to the problem, just as PRP alone leaves a contained cartilage void unaddressed.

Where both may apply is when underlying joint inflammation could compromise the repair environment for a patient undergoing ChondroFiller injection. PRP may then serve as a biological adjunct — before or after the scaffold procedure — not as a substitute for it, but as a means of creating more favourable conditions. Two mechanisms, two distinct roles in the same hip joint.

For patients in Lincolnshire and the wider non-London catchment, Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral; consultations are available at MSK House in Sleaford and The Keep Clinic in Grantham.

The choice between these treatments — or whether both are relevant — ultimately turns on what the MRI reveals: focal defect or diffuse degeneration, structural void or compromised biological environment. That imaging distinction is where every other decision in this pathway begins.